![6,7-Dihydro-4-benzo[b]thiophenone](/upload/1124/V69029.png)
| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
6,7-Dihydro-4-benzo[b]thiophenone is used as a reagent in the synthesis of anilinopyrimidines as IKKβ inhibitors and in the synthesis of peptidomimetics as HIV-1 protease inhibitors. IKKβ (IκB kinase β) is a key enzyme in the NF-κB signaling pathway, which is involved in inflammation, immunity, and cell survival. IKKβ inhibitors are being investigated for the treatment of inflammatory diseases and cancer. HIV-1 protease is an essential enzyme for the replication of HIV-1, and its inhibitors are used in the treatment of HIV/AIDS. The compound's benzothiophene core provides a scaffold for the synthesis of inhibitors targeting these enzymes. The ketone functionality allows for further functionalization to optimize target engagement and pharmacological properties. The compound serves as a building block for the synthesis of various biologically active molecules targeting inflammatory, infectious, and oncological diseases.
|
|---|---|
| ln Vitro |
In vitro, 6,7-dihydro-4-benzo[b]thiophenone is used as a reagent in the synthesis of anilinopyrimidines as IKKβ inhibitors and in the synthesis of peptidomimetics as HIV-1 protease inhibitors. It is a biochemical compound that may be utilized as a biomaterial or organic/chemical reagent for biomedical research. In medicinal chemistry, it serves as a building block for the synthesis of benzothiophene-containing drug candidates targeting IKKβ and HIV-1 protease. Its ketone functionality allows for derivatization through condensation, reduction, and other transformations. The benzothiophene core provides a rigid, aromatic scaffold that can interact with biological targets through π-π stacking and hydrophobic interactions. In organic synthesis, it is used as a versatile building block for creating complex molecules efficiently.
|
| Enzyme Assay |
Cell-free assays for 6,7-dihydro-4-benzo[b]thiophenone are focused on its use as a chemical reagent. Standard protocols for the synthesis of anilinopyrimidines as IKKβ inhibitors involve the compound as a key intermediate. For the synthesis of peptidomimetics as HIV-1 protease inhibitors, the compound is also used as a reagent. The reaction progress is monitored by TLC or HPLC, and the products are purified by column chromatography. The compound's reactivity can be studied using various analytical techniques including NMR spectroscopy, mass spectrometry, and HPLC. Its use as a building block for pharmaceutical synthesis involves standard organic synthesis procedures.
|
| Cell Assay |
Cellular assays are not performed with the parent compound 6,7-dihydro-4-benzo[b]thiophenone. Instead, its derivatives, such as IKKβ inhibitors and HIV-1 protease inhibitors, are evaluated in cell-based systems. For IKKβ inhibitors, cell lines are treated with the derivatives, and NF-κB activity, inflammatory cytokine production, and cell viability are measured. For HIV-1 protease inhibitors, HIV-infected cells are treated with the derivatives, and viral replication is measured. The parent compound itself is not used as a test article in cell-based experiments due to its role as a synthetic building block.
|
| Animal Protocol |
Animal studies are not conducted with the parent compound 6,7-dihydro-4-benzo[b]thiophenone. Its derivatives, such as IKKβ inhibitors and HIV-1 protease inhibitors, are evaluated in animal models of inflammatory diseases, cancer, and HIV/AIDS. The parent compound itself is not administered to animals, as it is a synthetic intermediate. Toxicity and pharmacological profiles for the parent compound are inferred from related benzothiophene derivatives.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 6,7-dihydro-4-benzo[b]thiophenone are not available, as the compound is primarily a chemical intermediate rather than a drug candidate. With a molecular weight of 152.21 g/mol and a melting point of 34 °C, the compound would be expected to have moderate lipophilicity and membrane permeability if administered. However, comprehensive pharmacokinetic studies including absorption, distribution, metabolism, and excretion have not been performed, as the compound is not intended for therapeutic use. For research purposes, the compound is typically handled as a neat chemical and not administered to living organisms for pharmacokinetic profiling.
|
| Additional Infomation |
6,7-Dihydro-4-benzo[b]thiophenone is a research chemical, not an approved drug. It has no clinical trial or marketing approval status for therapeutic use. The compound is used as a reagent in the synthesis of anilinopyrimidines as IKKβ inhibitors and in the synthesis of peptidomimetics as HIV-1 protease inhibitors. It is a biochemical compound that may be utilized as a biomaterial or organic/chemical reagent for biomedical research. The compound has a purity of ≥95.0% by GC and appears as a white to light yellow to light orange powder or lump with a melting point of 34 °C and a boiling point of 92 °C at 1 mmHg.
|
| Molecular Formula |
C8H8OS
|
|---|---|
| Molecular Weight |
152.21
|
| Exact Mass |
152.029
|
| CAS # |
13414-95-4
|
| PubChem CID |
83418
|
| Appearance |
<38°C Powder,>40°C Liquid
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
267.0±9.0 °C at 760 mmHg
|
| Melting Point |
38-40ºC(lit.)
|
| Flash Point |
115.3±18.7 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.595
|
| LogP |
2.39
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
10
|
| Complexity |
155
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C([H])=C([H])C2C(C([H])([H])C([H])([H])C([H])([H])C1=2)=O
|
| InChi Key |
GJEKNELSXNSYAQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H8OS/c9-7-2-1-3-8-6(7)4-5-10-8/h4-5H,1-3H2
|
| Chemical Name |
6,7-dihydro-5H-1-benzothiophen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5699 mL | 32.8494 mL | 65.6987 mL | |
| 5 mM | 1.3140 mL | 6.5699 mL | 13.1397 mL | |
| 10 mM | 0.6570 mL | 3.2849 mL | 6.5699 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
